acute myeloid leukemia
Conditions
Interventions
1:rHuG-CSF + shorten the time of BCL2 inhibitor + Azacitidine
Sponsors
Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 years or older and a confirmed diagnosis of previously untreated AML according to World Health Organization criteria with at least one of the following conditions: 1) Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or 3; 2) Cardiac history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction = 30 mL/min to 1.5 to <= 3.0 ULN; 3) Patients have any other comorbidity that the physician judges to be incompatible with intensive chemotherapy; 4) patients willing to participate; 2. older than 75 years old untreate AML; 3. high-risk MDS 4. Patients should have a life expectancy of at least 12 weeks.
Exclusion criteria
Exclusion criteria: 1. Patient has received treatment with hypomethylating agent, and/or venetoclax; 2. Patient has sever liver dis-function (Child-pugh C),or renal dis-function( a creatinine <=15 mL/min) 3. physician judges to be incompatible with this treatment protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR;overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| CR and CRi;safety;Evevt-free survival; | — |
Countries
China
Contacts
Public ContactJuan Huang
Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital
Outcome results
None listed